Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03638583 · ClinicalTrials.gov registry record
Alzheimer Prevention Trials (APT) Webstudy
A clinical trial of Alzheimer Disease and Dementia, sponsored by University of Southern California.
- Recruiting
- Registry status
- 200,000
- Enrollment target
- 1
- Study location
NCT03638583 is a study of Alzheimer Disease and Dementia that is actively recruiting participants, run by University of Southern California. The registered enrollment target is 200,000 participants, above the 2,097-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (9437% higher). The trial reports 1 study location across 1 state.
The verdict
NCT03638583, a study of Alzheimer Disease and Dementia, is actively recruiting participants, sponsored by University of Southern California.
- RECRUITING
- Registry status
- 200,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of the Alzheimer Prevention Trials (APT) Webstudy is to accelerate enrollment for Alzheimer's disease (AD) clinical trials by identifying and tracking individuals who may be at higher risk for developing AD dementia.
Conditions Studied
Study Locations (1)
California
- Https://Www.Aptwebstudy.Org - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200,000 participants |
| Start Date | 2017-12-20 |
| Est. Completion | 2026-04-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03638583
The ClinicalTrials.gov registry entry for NCT03638583 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 200,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 2,097-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (9437% higher). The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 0 interventions.
NCT03638583 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03638583 about?
NCT03638583 is a clinical study titled "Alzheimer Prevention Trials (APT) Webstudy". The goal of the Alzheimer Prevention Trials (APT) Webstudy is to accelerate enrollment for Alzheimer's disease (AD) clinical trials by identifying and tracking individuals who may be at higher risk for developing AD dementia.
What is the current status of trial NCT03638583?
This trial is currently recruiting. The enrollment target is 200,000 participants. The study started on 2017-12-20. Estimated completion is 2026-04-30.
What conditions does trial NCT03638583 study?
This clinical trial studies the following conditions: Alzheimer Disease, Dementia.
Who is sponsoring clinical trial NCT03638583?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03638583 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
RECRUITING · Phase 3
-
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
RECRUITING · Phase 4
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
RECRUITING · NA
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Cognitive Neurology Unit Clinical Registry
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.